EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Mersana Therapeutics's enterprise value is $228.79 Mil.
Mersana Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $36.86 Mil. Therefore, Mersana Therapeutics's EV-to-Revenue for today is 6.21.
The historical rank and industry rank for Mersana Therapeutics's EV-to-Revenue or its related term are showing as below:
MRSN'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2.91 Med: 13.93 Max: 1916.9
Current: 6.21
During the past 9 years, the highest EV-to-Revenue of Mersana Therapeutics was 1916.90. The lowest was -2.91. And the median was 13.93.
MRSN's EV-to-Revenue is ranked better than 52.86% of 1031
companies
in the Biotechnology industry
Industry Median: 7.58
vs MRSN: 6.21
As of today (2024-04-19), Mersana Therapeutics's stock price is $3.24.
Mersana Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.32. Therefore, Mersana Therapeutics's PS Ratio for today is 10.19.
Mersana Therapeutics EV-to-Revenue Historical Data
The historical data trend for Mersana Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Mersana Therapeutics Annual Data
Trend
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
3.99
1,924.33
7,411.62
13.99
2.84
Mersana Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
13.99
6.49
3.74
-1.31
2.84
Competitive Comparison
For the Biotechnology subindustry, Mersana Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mersana Therapeutics EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Mersana Therapeutics's EV-to-Revenue falls into.
Mersana Therapeutics's current Enterprise Value is $228.79 Mil.
Mersana Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mersana Therapeutics's share price for today is $3.24.
Mersana Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mersana Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Mersana Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mersana Therapeutics (Mersana Therapeutics) Business Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRSN has been successfully added to your 